Novel Biomarkers of Abdominal Aortic Aneurysm Disease: Identifying Gaps and Dispelling Misperceptions
-
- Demetrios Moris
- First Department of Surgery, Vascular Unit, “Laiko” General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527 Athens, Greece
-
- Eleftherios Mantonakis
- First Department of Surgery, Vascular Unit, “Laiko” General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527 Athens, Greece
-
- Efthymios Avgerinos
- Division of Vascular Surgery, University of Pittsburgh, Pittsburgh, PA 15213-2582, USA
-
- Marinos Makris
- Imperial College, London SW7 2AZ, UK
-
- Chris Bakoyiannis
- First Department of Surgery, Vascular Unit, “Laiko” General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527 Athens, Greece
-
- Emmanuel Pikoulis
- First Department of Surgery, Vascular Unit, “Laiko” General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527 Athens, Greece
-
- Sotirios Georgopoulos
- First Department of Surgery, Vascular Unit, “Laiko” General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527 Athens, Greece
説明
<jats:p>Abdominal aortic aneurysm (AAA) is a prevalent and potentially life-threatening disease. Early detection by screening programs and subsequent surveillance has been shown to be effective at reducing the risk of mortality due to aneurysm rupture. The aim of this review is to summarize the developments in the literature concerning the latest biomarkers (from 2008 to date) and their potential screening and therapeutic values. Our search included human studies in English and found numerous novel biomarkers under research, which were categorized in 6 groups. Most of these studies are either experimental or hampered by their low numbers of patients. We concluded that currently no specific laboratory markers allow screeing for the disease and monitoring its progression or the results of treatment. Further studies and studies in larger patient groups are required in order to validate biomarkers as cost-effective tools in the AAA disease.</jats:p>
収録刊行物
-
- BioMed Research International
-
BioMed Research International 2014 1-13, 2014
Hindawi Limited